Long-term effects of theophylline in patients with symptomatic atrial fibrillation and a slow ventricular response

N. Paparella, R. Cappato, R. Pirani, P. Yiannacopulu, P. Alboni

Research output: Contribution to journalArticle

Abstract

The purpose of the present study was to investigate the long-term effects of oral theophylline in patients with atrial fibrillation (AF) and a slow ventricular response. In 17 patients (age: 78 ± 9 years) with symptomatic AF and a slow ventricular response not related to drugs, resting electrocardiogram and 24-hour Holter recording were performed before and 5-6 days after the administration of slow-release theophylline (700 mg daily) and successively every 3 months during the long-term phase. Fourteen patients had organic heart disease, 13 complained of syncope or presyncope and 4 of asthenia and easy fatigue. At the steady-state evaluation, theophylline significantly increased resting heart rate (HR) by 42%, mean 24-hour HR by 31% and minimal 24-hour HR by 34%. Cardiac pauses > 2500 ms disappeared or markedly decreased. The daily number of wide QRS complexes increased. Serum theophylline level was 13 ± 5 ng/ml. During the follow-up period (20 ± 18 months) the mean daily theophylline dosage was 450 mg and the mean serum theophylline level 9 ng/ml. Seven patients died: 1 because of heart failure and 6 because of non cardiac death. One patient complained of a syncopal episode during one visit. The drug markedly reduced asthenia and easy fatigue. During the long-term phase, HR increased spontaneously in 3 patients and the treatment was interrupted. In 2 patients theophylline had to be discontinued because of gastric intolerance. During long-term therapy, the HR was similar to that observed at the steady-state evaluation despite the reduction in the daily dosage. These data suggest theophylline as an effective therapy in most patients with symptomatic AF and a show ventricular response.

Original languageEnglish
Pages (from-to)639-644
Number of pages6
JournalNew Trends in Arrhythmias
Volume9
Issue number3
Publication statusPublished - 1993

Fingerprint

Theophylline
Atrial Fibrillation
Heart Rate
Syncope
Asthenia
Fatigue
Serum
Pharmaceutical Preparations
Heart Diseases
Stomach
Electrocardiography
Therapeutics
Heart Failure

Keywords

  • arrhythmias
  • atrial fibrillation
  • atrio-ventricular conduction
  • theophylline

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term effects of theophylline in patients with symptomatic atrial fibrillation and a slow ventricular response. / Paparella, N.; Cappato, R.; Pirani, R.; Yiannacopulu, P.; Alboni, P.

In: New Trends in Arrhythmias, Vol. 9, No. 3, 1993, p. 639-644.

Research output: Contribution to journalArticle

Paparella, N. ; Cappato, R. ; Pirani, R. ; Yiannacopulu, P. ; Alboni, P. / Long-term effects of theophylline in patients with symptomatic atrial fibrillation and a slow ventricular response. In: New Trends in Arrhythmias. 1993 ; Vol. 9, No. 3. pp. 639-644.
@article{f6ff9b8907654323b03c8a308757b38f,
title = "Long-term effects of theophylline in patients with symptomatic atrial fibrillation and a slow ventricular response",
abstract = "The purpose of the present study was to investigate the long-term effects of oral theophylline in patients with atrial fibrillation (AF) and a slow ventricular response. In 17 patients (age: 78 ± 9 years) with symptomatic AF and a slow ventricular response not related to drugs, resting electrocardiogram and 24-hour Holter recording were performed before and 5-6 days after the administration of slow-release theophylline (700 mg daily) and successively every 3 months during the long-term phase. Fourteen patients had organic heart disease, 13 complained of syncope or presyncope and 4 of asthenia and easy fatigue. At the steady-state evaluation, theophylline significantly increased resting heart rate (HR) by 42{\%}, mean 24-hour HR by 31{\%} and minimal 24-hour HR by 34{\%}. Cardiac pauses > 2500 ms disappeared or markedly decreased. The daily number of wide QRS complexes increased. Serum theophylline level was 13 ± 5 ng/ml. During the follow-up period (20 ± 18 months) the mean daily theophylline dosage was 450 mg and the mean serum theophylline level 9 ng/ml. Seven patients died: 1 because of heart failure and 6 because of non cardiac death. One patient complained of a syncopal episode during one visit. The drug markedly reduced asthenia and easy fatigue. During the long-term phase, HR increased spontaneously in 3 patients and the treatment was interrupted. In 2 patients theophylline had to be discontinued because of gastric intolerance. During long-term therapy, the HR was similar to that observed at the steady-state evaluation despite the reduction in the daily dosage. These data suggest theophylline as an effective therapy in most patients with symptomatic AF and a show ventricular response.",
keywords = "arrhythmias, atrial fibrillation, atrio-ventricular conduction, theophylline",
author = "N. Paparella and R. Cappato and R. Pirani and P. Yiannacopulu and P. Alboni",
year = "1993",
language = "English",
volume = "9",
pages = "639--644",
journal = "New Trends in Arrhythmias",
issn = "0393-5302",
number = "3",

}

TY - JOUR

T1 - Long-term effects of theophylline in patients with symptomatic atrial fibrillation and a slow ventricular response

AU - Paparella, N.

AU - Cappato, R.

AU - Pirani, R.

AU - Yiannacopulu, P.

AU - Alboni, P.

PY - 1993

Y1 - 1993

N2 - The purpose of the present study was to investigate the long-term effects of oral theophylline in patients with atrial fibrillation (AF) and a slow ventricular response. In 17 patients (age: 78 ± 9 years) with symptomatic AF and a slow ventricular response not related to drugs, resting electrocardiogram and 24-hour Holter recording were performed before and 5-6 days after the administration of slow-release theophylline (700 mg daily) and successively every 3 months during the long-term phase. Fourteen patients had organic heart disease, 13 complained of syncope or presyncope and 4 of asthenia and easy fatigue. At the steady-state evaluation, theophylline significantly increased resting heart rate (HR) by 42%, mean 24-hour HR by 31% and minimal 24-hour HR by 34%. Cardiac pauses > 2500 ms disappeared or markedly decreased. The daily number of wide QRS complexes increased. Serum theophylline level was 13 ± 5 ng/ml. During the follow-up period (20 ± 18 months) the mean daily theophylline dosage was 450 mg and the mean serum theophylline level 9 ng/ml. Seven patients died: 1 because of heart failure and 6 because of non cardiac death. One patient complained of a syncopal episode during one visit. The drug markedly reduced asthenia and easy fatigue. During the long-term phase, HR increased spontaneously in 3 patients and the treatment was interrupted. In 2 patients theophylline had to be discontinued because of gastric intolerance. During long-term therapy, the HR was similar to that observed at the steady-state evaluation despite the reduction in the daily dosage. These data suggest theophylline as an effective therapy in most patients with symptomatic AF and a show ventricular response.

AB - The purpose of the present study was to investigate the long-term effects of oral theophylline in patients with atrial fibrillation (AF) and a slow ventricular response. In 17 patients (age: 78 ± 9 years) with symptomatic AF and a slow ventricular response not related to drugs, resting electrocardiogram and 24-hour Holter recording were performed before and 5-6 days after the administration of slow-release theophylline (700 mg daily) and successively every 3 months during the long-term phase. Fourteen patients had organic heart disease, 13 complained of syncope or presyncope and 4 of asthenia and easy fatigue. At the steady-state evaluation, theophylline significantly increased resting heart rate (HR) by 42%, mean 24-hour HR by 31% and minimal 24-hour HR by 34%. Cardiac pauses > 2500 ms disappeared or markedly decreased. The daily number of wide QRS complexes increased. Serum theophylline level was 13 ± 5 ng/ml. During the follow-up period (20 ± 18 months) the mean daily theophylline dosage was 450 mg and the mean serum theophylline level 9 ng/ml. Seven patients died: 1 because of heart failure and 6 because of non cardiac death. One patient complained of a syncopal episode during one visit. The drug markedly reduced asthenia and easy fatigue. During the long-term phase, HR increased spontaneously in 3 patients and the treatment was interrupted. In 2 patients theophylline had to be discontinued because of gastric intolerance. During long-term therapy, the HR was similar to that observed at the steady-state evaluation despite the reduction in the daily dosage. These data suggest theophylline as an effective therapy in most patients with symptomatic AF and a show ventricular response.

KW - arrhythmias

KW - atrial fibrillation

KW - atrio-ventricular conduction

KW - theophylline

UR - http://www.scopus.com/inward/record.url?scp=0027738130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027738130&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027738130

VL - 9

SP - 639

EP - 644

JO - New Trends in Arrhythmias

JF - New Trends in Arrhythmias

SN - 0393-5302

IS - 3

ER -